Summary

The SELECT-LV trial shows that direct, wireless endocardial left ventricular pacing for cardiac resynchronization therapy is feasible and results in significant reductions in QRS duration, synchronous left ventricular stimulation, evidence of electrical and structural remodeling, and improvement in left ventricular ejection fraction. There is no evidence of pericardial tamponade, and there are few procedural adverse events.